Charles Schwab Investment Management Inc Krystal Biotech, Inc. Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 243,170 shares of KRYS stock, worth $37.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

243,170

Previous 240,216 1.23%

Holding current value

$37.6 Million

Previous $43.7 Million 12.79%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$156.64 - $199.61 $462,714 - $589,647	2,954 Added 1.23%	243,170 $38.1 Million
Q3 2024 Nov 12, 2024	BUY	$174.7 - $213.66 $3.46 Million - $4.23 Million	19,777 Added 8.97%	240,216 $43.7 Million
Q2 2024 Aug 12, 2024	BUY	$153.12 - $183.64 $4.83 Million - $5.79 Million	31,536 Added 16.69%	220,439 $40.5 Million
Q1 2024 May 08, 2024	BUY	$108.01 - $179.35 $417,458 - $693,187	3,865 Added 2.09%	188,903 $33.6 Million
Q4 2023 Feb 06, 2024	BUY	$96.0 - $128.29 $504,768 - $674,548	5,258 Added 2.92%	185,038 $23 Million
Q3 2023 Nov 08, 2023	BUY	$108.51 - $130.22 $1.91 Million - $2.29 Million	17,614 Added 10.86%	179,780 $20.9 Million
Q2 2023 Aug 09, 2023	BUY	$78.48 - $130.32 $178,698 - $296,738	2,277 Added 1.42%	162,166 $19 Million
Q1 2023 May 11, 2023	SELL	$72.39 - $84.27 $52,555 - $61,180	-726 Reduced 0.45%	159,889 $12.8 Million
Q4 2022 Feb 13, 2023	BUY	$63.14 - $79.9 $274,280 - $347,085	4,344 Added 2.78%	160,615 $12.7 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $487,607 - $619,565	7,519 Added 5.05%	156,271 $10.9 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $19,816 - $29,755	405 Added 0.27%	148,752 $9.77 Million
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $453,820 - $629,448	8,729 Added 6.25%	148,347 $9.87 Million
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $566,655 - $1.26 Million	14,234 Added 11.35%	139,618 $9.77 Million
Q3 2021 Nov 16, 2021	BUY	$52.01 - $71.77 $172,257 - $237,702	3,312 Added 2.71%	125,384 $6.55 Million
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $470,213 - $619,131	7,567 Added 6.61%	122,072 $8.3 Million
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $910,670 - $1.31 Million	15,326 Added 15.45%	114,505 $8.82 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $100,909 - $152,406	2,483 Added 2.57%	99,179 $5.95 Million
Q3 2020 Nov 13, 2020	BUY	$37.76 - $48.49 $760,788 - $976,976	20,148 Added 26.32%	96,696 $4.16 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $283,094 - $458,700	7,645 Added 11.1%	76,548 $3.17 Million
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $53,895 - $101,019	1,539 Added 2.28%	68,903 $2.98 Million
Q4 2019 Feb 07, 2020	BUY	$33.17 - $65.23 $44,315 - $87,147	1,336 Added 2.02%	67,364 $3.73 Million
Q3 2019 Nov 08, 2019	BUY	$34.72 - $51.3 $1.57 Million - $2.32 Million	45,189 Added 216.85%	66,028 $2.29 Million
Q2 2019 Aug 09, 2019	BUY	$27.2 - $41.2 $566,820 - $858,566	20,839 New	20,839 $840,000

Others Institutions Holding KRYS

# of Institutions

309

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Krystal Biotech, Inc. Transaction History